Program
Alveltamig
Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Neuroendocrine · Prostatic Neoplasms, led by 2 companies.
Drug pageAlveltamig: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Suzhou Zelgen Biopharmaceuticalsits history only | 1010 open or running | phase 3since Sep 16, 2025 | Jul 28, 2023 | Dec 2026phase 1 · NCT06592638 |
| Hansoh Pharmaceutical Group | 11 open or running | phase 1since Aug 13, 2026 | Aug 13, 2026 | Sep 15, 2028phase 1 · NCT07892625 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hansoh Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 29, 2026Named alveltamigINNProposed as its International Nonproprietary Name in WHO's List 134 · before, ZG006
- Aug 13, 2026First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT07892625 · 338 planned
Ahead
- Sep 15, 2028Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT07892625
TargetBeta
“A trispecific T-cell engaging (TCE) antibody directed against two different epitopes of the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) and the T-cell surface antigen CD3, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tarlatamabrule | Amgen | phase 3 | 13 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| gocatamig | Merck | phase 3 | 4 |
| SHR-7787 | Jiangsu HengRui Medicine | phase 2 | 1 |
| clesitamig | Hoffmann-La Roche | phase 1 | 2 |
| HLX3901 | Fosun Pharma | phase 1 | 1 |
Studies
The one study Hansoh Pharmaceutical Group leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07892625Small Cell Lung Carcinoma | 1 | Not yet recruiting | Sep 15, 2028 | 338 |
How it is read
Names in the registry
- “ZG006”, 11 entries
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 7 studies
- Carcinoma, Neuroendocrine, 2 studies
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.